Related Experiment Video

Updated: Jun 1, 2026

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
10:02

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Effect of osmotic-release oral system methylphenidate on different domains of attention and executive functioning in

Nathan J Blum1, Abbas F Jawad1, Angela T Clarke1

  • 1Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA University of Pennsylvania School of Medicine, Philadelphia, PA Department of Psychology, West Chester University of Pennsylvania, West Chester, PA, USA.

Developmental Medicine and Child Neurology
|May 19, 2011
PubMed

Insights

Osmotic-release oral system (OROS) methylphenidate improved response inhibition in children with attention-deficit-hyperactivity disorder (ADHD). Other cognitive functions like attention and working memory showed variable or no improvement.

Area of Science:

  • Pediatric Neurology
  • Child Psychology
  • Pharmacology

Background:

  • Attention-deficit-hyperactivity disorder (ADHD) is a neurodevelopmental disorder impacting executive functions.
  • Methylphenidate is a common pharmacotherapy for ADHD, with various delivery systems available.
  • Osmotic-release oral system (OROS) methylphenidate offers extended-release benefits.

Purpose of the Study:

  • To evaluate the efficacy of OROS methylphenidate on specific components of attention and executive functioning in children with ADHD.
  • To determine if OROS methylphenidate treatment leads to improvements in response inhibition, attentional control, sustained attention, selective attention, and working memory.

Main Methods:

  • A double-blind, placebo-controlled crossover trial involving 30 children diagnosed with ADHD combined type.
  • Participants received their clinically determined optimal dose of OROS methylphenidate or placebo for one week each.
  • A comprehensive neuropsychological battery assessed various cognitive domains, including response inhibition, attentional control, sustained attention, selective attention, and working memory.

Main Results:

  • Significant improvement was observed in two out of three response inhibition tasks (p<0.01) with OROS methylphenidate compared to placebo.
  • Partial improvements were noted in attentional control (one of two tasks) and sustained attention (one of five measures).
  • No significant improvements were found in selective attention or working memory tasks.

Conclusions:

  • OROS methylphenidate, at the clinically effective dose, demonstrates a positive impact on response inhibition in children with ADHD.
  • Treatment effects on other executive functions, including attention and working memory, were inconsistent or not evident.
  • Further research may be needed to explore the nuanced effects of OROS methylphenidate on diverse cognitive domains in pediatric ADHD.
Abstract

More Related Videos

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol13:09

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol

Published on: April 1, 2018

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Oppositional Defiant Disorder01:30

Oppositional Defiant Disorder

A persistent pattern of angry or irritable mood, defiant behavior, or vindictiveness characterizes Oppositional Defiant Disorder (ODD). Symptoms must occur over at least six months, involve interactions with individuals beyond siblings, and meet specific diagnostic criteria to be clinically significant. The disorder affects emotional regulation, social interactions, and behavior, often manifesting early in life and influencing long-term development and functioning.
Diagnostic Criteria and...